Avidity Partners 13F holdings, Q4 2025
Holdings as of December 31, 2025 · filings on SEC EDGAR · latest filing →
Avidity Partners disclosed 39 US equity positions worth $346.7m in its Q4 2025 13F filing. The largest position was DNTH at 25.0% of the reported book, followed by CGON and JBIO. Against the Q3 2025 filing, it opened 11 new positions, added to 5 and reduced 19 among the top 39 holdings.
What did Avidity Partners own in Q4 2025? Top 39 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2025 |
|---|---|---|---|---|---|---|---|
| 1 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 25.0% | $86.7m | 2,104,184 | -34% | reduced |
| 2 | CGON CG ONCOLOGY INC | Healthcare | 17.6% | $61.1m | 1,472,699 | -8% | reduced |
| 3 | JBIO JADE BIOSCIENCES INC | 6.2% | $21.6m | 1,400,708 | 24% | added | |
| 4 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 5.8% | $20.0m | 660,424 | 0% | held |
| 5 | TEVA TEVA PHARMACEUTICAL INDS LTD | Healthcare | 3.8% | $13.0m | 417,300 | -18% | reduced |
| 6 | BSX BOSTON SCIENTIFIC CORP | Healthcare | 3.1% | $10.9m | 114,500 | -30% | reduced |
| 7 | MDT MEDTRONIC PLC | Healthcare | 3.0% | $10.3m | 107,600 | -44% | reduced |
| 8 | CATX PERSPECTIVE THERAPEUTICS INC | 2.5% | $8.8m | 3,210,733 | 7% | added | |
| 9 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 2.4% | $8.4m | 21,000 | – | new |
| 10 | RGEN REPLIGEN CORP | Healthcare | 2.4% | $8.2m | 50,300 | 116% | added |
| 11 | CNTX CONTEXT THERAPEUTICS INC | 2.3% | $8.1m | 5,504,855 | -39% | reduced | |
| 12 | MCK MCKESSON CORP | Healthcare | 2.3% | $7.8m | 9,520 | 64% | added |
| 13 | ICLR ICON PLC | Healthcare | 1.7% | $6.0m | 33,100 | – | new |
| 14 | A AGILENT TECHNOLOGIES INC | Healthcare | 1.6% | $5.6m | 41,500 | – | new |
| 15 | PFE PFIZER INC | Healthcare | 1.5% | $5.1m | 203,600 | -44% | reduced |
| 16 | CNC CENTENE CORP DEL | Healthcare | 1.4% | $4.9m | 119,400 | – | new |
| 17 | KVUE KENVUE INC | Consumer Defensive | 1.2% | $4.0m | 232,800 | -12% | reduced |
| 18 | DHR DANAHER CORPORATION | Healthcare | 1.1% | $3.9m | 17,000 | -69% | reduced |
| 19 | TMO THERMO FISHER SCIENTIFIC INC | Healthcare | 1.1% | $3.9m | 6,700 | -65% | reduced |
| 20 | NVO NOVO-NORDISK A S | Healthcare | 1.0% | $3.4m | 67,300 | – | new |
| 21 | PHAT PHATHOM PHARMACEUTICALS INC | 1.0% | $3.4m | 206,076 | -33% | reduced | |
| 22 | EHC ENCOMPASS HEALTH CORP | Healthcare | 1.0% | $3.4m | 31,600 | -25% | reduced |
| 23 | CI THE CIGNA GROUP | Healthcare | 0.9% | $3.2m | 11,600 | -30% | reduced |
| 24 | COR CENCORA INC | Healthcare | 0.9% | $3.2m | 9,400 | -51% | reduced |
| 25 | INSM INSMED INC | Healthcare | 0.9% | $3.1m | 17,700 | 53% | added |
| 26 | WAT WATERS CORP | Healthcare | 0.9% | $3.1m | 8,100 | – | new |
| 27 | ACAD ACADIA PHARMACEUTICALS INC | Healthcare | 0.8% | $2.9m | 106,900 | -26% | reduced |
| 28 | GMAB GENMAB A/S | Healthcare | 0.8% | $2.8m | 92,000 | -63% | reduced |
| 29 | NTRA NATERA INC | Healthcare | 0.8% | $2.7m | 11,800 | -83% | reduced |
| 30 | IMUX IMMUNIC INC | Healthcare | 0.7% | $2.5m | 4,699,411 | 0% | held |
| 31 | ACHC ACADIA HEALTHCARE COMPANY IN | Healthcare | 0.7% | $2.4m | 169,000 | – | new |
| 32 | ITGR INTEGER HLDGS CORP | Healthcare | 0.7% | $2.3m | 29,800 | – | new |
| 33 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 0.6% | $2.2m | 140,300 | 0% | held |
| 34 | PALVELLA THERAPEUTICS INC NE | 0.6% | $2.0m | 19,300 | – | new | |
| 35 | HQY HEALTHEQUITY INC | Healthcare | 0.4% | $1.5m | 16,900 | -33% | reduced |
| 36 | SCYX SCYNEXIS INC | 0.4% | $1.3m | 2,081,660 | -38% | reduced | |
| 37 | IQV IQVIA HLDGS INC | Healthcare | 0.3% | $991.8k | 4,400 | – | new |
| 38 | KPTI KARYOPHARM THERAPEUTICS INC | 0.3% | $990.4k | 134,566 | 0% | held | |
| 39 | CORT CORCEPT THERAPEUTICS INC | Healthcare | 0.2% | $765.6k | 22,000 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.